artelo biosciences inc - ARTL
ARTL
Close Chg Chg %
1.16 -0.03 -2.59%
Closed Market
1.13
-0.03 (2.59%)
Volume: 18.58K
Last Updated:
Nov 21, 2024, 4:00 PM EDT
Company Overview: artelo biosciences inc - ARTL
ARTL Key Data
| Open $1.15 | Day Range 1.13 - 1.17 |
| 52 Week Range 1.00 - 1.75 | Market Cap $3.71M |
| Shares Outstanding 3.23M | Public Float 3.20M |
| Beta 1.35 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.84 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 27.58K |
ARTL Performance
| 1 Week | 8.65% | ||
| 1 Month | -3.42% | ||
| 3 Months | -11.72% | ||
| 1 Year | -11.72% | ||
| 5 Years | -97.34% |
ARTL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
3
Full Ratings ➔
About artelo biosciences inc - ARTL
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.
ARTL At a Glance
Artelo Biosciences, Inc.
505 Lomas Santa Fe
Solana Beach, California 92075
| Phone | 1-858-925-7049 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -9,289,000.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
ARTL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.38 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.63 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.004 |
ARTL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,548,166.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ARTL Liquidity
| Current Ratio | 8.505 |
| Quick Ratio | 8.505 |
| Cash Ratio | 8.076 |
ARTL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -55.511 |
| Return on Equity | -59.631 |
| Return on Total Capital | -78.887 |
| Return on Invested Capital | -59.587 |
ARTL Capital Structure
| Total Debt to Total Equity | 0.196 |
| Total Debt to Total Capital | 0.195 |
| Total Debt to Total Assets | 0.176 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Artelo Biosciences Inc - ARTL
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| - | - | - | 500.0000000035 | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | - | 500.0000000035 | - |
Depreciation
| - | - | - | 500.0000000035 | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | -1.96% | -100.00% | - |
Gross Income
| - | - | - | (500.0000000035) | - |
Gross Income Growth
| - | - | +1.96% | +100.00% | - |
Gross Profit Margin
| - | - | - | - | - |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 4.69M | 7.44M | 10.29M | 9.93M | |
Research & Development
| 1.92M | 2.84M | 4.32M | 5.70M | |
Other SG&A
| 2.77M | 4.60M | 5.96M | 4.23M | |
SGA Growth
| +46.00% | +58.82% | +38.25% | -3.47% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (29.50K) | (2.00K) | (207.00K) | (641.00K) | |
EBIT after Unusual Expense
| (4.66M) | (7.44M) | (10.08M) | (9.29M) | |
Non Operating Income/Expense
| - | 1.41K | 2.00K | 2.00K | |
Non-Operating Interest Income
| - | - | 2.00K | 2.00K | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 5.00K | - |
Interest Expense Growth
| - | - | - | -100.00% | - |
Gross Interest Expense
| - | - | - | 5.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (4.65M) | (7.44M) | (10.08M) | (9.29M) | |
Pretax Income Growth
| -114.29% | -59.77% | -35.58% | +7.87% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (4.65M) | (7.44M) | (10.08M) | (9.29M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (4.65M) | (7.44M) | (10.08M) | (9.29M) | |
Net Income Growth
| -114.29% | -59.77% | -35.58% | +7.87% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (4.65M) | (7.44M) | (10.08M) | (9.29M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (4.65M) | (7.44M) | (10.08M) | (9.29M) | |
EPS (Basic)
| -1.2555 | -5.9733 | -3.5591 | -3.1382 | |
EPS (Basic) Growth
| -25.56% | -375.77% | +40.42% | +11.83% | |
Basic Shares Outstanding
| 3.71M | 1.25M | 2.83M | 2.96M | |
EPS (Diluted)
| -1.2555 | -5.9733 | -3.5591 | -3.1382 | |
EPS (Diluted) Growth
| -25.56% | -375.77% | +40.42% | +11.83% | |
Diluted Shares Outstanding
| 3.71M | 1.25M | 2.83M | 2.96M | |
EBITDA
| (4.69M) | (7.44M) | (10.29M) | (9.93M) | |
EBITDA Growth
| -46.00% | -58.82% | -38.25% | +3.47% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 14.00 | |
| Number of Ratings | 3 | Current Quarters Estimate | -0.897 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -2.907 | |
| Last Quarter’s Earnings | -0.35 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.14 | Next Fiscal Year Estimate | -0.903 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | N/A | 3 | 3 |
| Mean Estimate | -0.90 | N/A | -2.91 | -0.90 |
| High Estimates | -0.19 | N/A | -1.03 | -0.48 |
| Low Estimate | -1.76 | N/A | -5.07 | -1.61 |
| Coefficient of Variance | -88.84 | N/A | -70.02 | -68.19 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 4 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Artelo Biosciences Inc - ARTL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Artelo Biosciences Inc - ARTL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 4, 2024 | Connie L. Matsui Director | 667 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | Douglas W. Blayney Director | 1,083 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | Steven Kelly Director | 9,634 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | Steven Kelly Director | 1,484 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | Steven Kelly Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Steven Kelly Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Steven Kelly Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Steven Kelly Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Steven Kelly Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Steven Kelly Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Connie L. Matsui Director | 1,083 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | Connie L. Matsui Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Connie L. Matsui Director | 667 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | Connie L. Matsui Director | 667 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | Connie L. Matsui Director | 10,634 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | Connie L. Matsui Director | 1,767 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | Connie L. Matsui Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Connie L. Matsui Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Connie L. Matsui Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Connie L. Matsui Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |